Below are the main words of each cluster derived from tf-idf, including and bio entities clusters.

  • Cluster 0    Therapies for Breast Cancer Fatigue

      • Reasoning: This cluster includes bio entities related to fatigue in breast cancer patients (attentional fatigue and mood/anxiety disorder) as well as potential therapeutic options for managing fatigue (modafinil and rebamipide). Other bio entities suggest potential novel therapies for breast cancer, including motesanib, a drug that inhibits tumor growth, and FGF-21, a protein that may reduce inflammation and promote metabolic health. Overall, this cluster suggests a focus on developing innovative strategies for managing fatigue in breast cancer patients, as well as identifying novel therapeutic targets for breast cancer treatment.

      Bio Entities: 'motesanib', 'attentional fatigue', 'balugrastim', 'Panagen', '"cancers of the mouth', 'efaproxiral', 'ADR-529', 'FVT', 'EPMs', 'modafinil', 'HCWs', 'BAT8001', 'D/deaf', 'IFX', 'rs3104746', 'SpM', 'MYL-1401H', 'proneurotensin', 'CROF', 'TEXT', 'esorubicin', 'mood/anxiety disorder', 'IMID', 'BCD-022', 'adiposity-related cancers', 'comorbid diseases', 'levofolinic acid', 'HSS', 'YACSs', 'degarelix', 'DPTS', '15-F(2t)-IsoP', 'rebamipide', 'SpA', 'RAHD', 'pHF', 'Paullinia cupana', 'Capilen', 'Ro 25-8315', 'LC-BC', 'FGF-21', 'rs13385191', 'CHESS', 'tubal sterilization', 'SARS-CoV-2 infection', 'BPM31543', 'Healthcare', 'HVOD', 'BCMO1', 'PERANTARA'

  • Cluster 1    Molecular Pathways of Breast Cancer

      • This cluster of scientists appears to be focused on molecular biology and genetics of breast cancer. The bio entities included are mainly genes, proteins and microRNAs which play important roles in various cellular processes such as cell cycle, DNA repair, proliferation, and differentiation. The cluster includes genes like Palb2, CLDN6, Runx1, TNFAIP8, and proteins like HEXIM1, PHF8, and Rab25, which are known to be associated with breast cancer progression, metastasis, and drug resistance. This cluster of scientists is likely investigating the underlying molecular mechanisms of breast cancer and looking for potential therapeutic targets. Based on the representative bio entities in Scientists Cluster 2, it seems to be focused on molecular and genetic aspects of breast cancer. Many of the bio entities listed are genes, proteins, and molecules involved in various cellular processes related to cancer development, such as cell signaling, cell cycle regulation, and DNA repair.

      Bio Entities: 'CLDN6', 'ITIH5', 'ARTN', 'TRIM37', 'EGOT', 'VASH2', 'JMJD2A', 'USP22', 'USP37', 'TNFAIP8', 'Rab25', 'hnRNPA2', 'ZNF652', 'PHF8', 'LINC00511', 'MIR302', 'Runx1', 'CYGB', 'HEXIM1', 'Palb2', 'Mcs1a', 'RPH3AL', 'RNF144A', 'SOX2OT', 'p66ShcA', 'CDK3', 'SLC20A1', 'SMURF1', 'GIHCG', 'NCAPG', 'TReP-132', 'Bcl-3', 'linc-ROR', 'T798', 'TBC1D24', 'PGCCs', 'miR-873', 'miR-330-3p', 'RNF126', 'EglN2', 'FEAT', 'CHRNA5', 'PRKD3', 'TPM2', 'sohlh2', 'SNHG1', 'PES1', 'DHCR24', 'MITA', 'MLN51'

  • Cluster 2    Therapeutic Targets

      • This cluster includes a variety of potential targets for drug development, such as Fc variants, CDK15, hinokitiol, and PIP4K2B, among others. These scientists are likely focusing on identifying and studying new targets for potential therapies for breast cancer.

      Bio Entities: 'Fc variants', 'levofolinate', 'SVF cells', 'MAMDC2', 'LADR', '20K-hGH', 'gCIS', 'FcRIIb', 'RLS', 'CDK15', 'BIM-23052', 'Buxus sempervirens', 'IPMC', 'LIPH', 'FevA', 'Virulizin', 'HLA-E*0103', 'Oxi4503', '22K-hGH', 'PRES', 'E7130', 'ZNF704', 'Sm-153 EDTMP', 'peg-G', 'hinokitiol', 'WMJ-8-B', 'RNA2DNAlign', 'PIP4K2B', 'Mn12Ac', 'T2Rs', 'PCAA', 'OAB', 'IL-1ß', 'BRCa', 'anti amphiphysin', 'NBTE', 'SPCA1a', 'pp40', 'penehyclidine hydrochloride', 'DLK', 'rs4402960', 'inattentional blindness', 'damnacanthal', 'MIR34a', 'BNIPOSpm', 'ADH2', 'UiO-66', 'SMRL', 'OMF', 'DDX54'

  • Cluster 3    Therapeutic Agents and Compounds

      • A cluster of scientific terms related to various substances and compounds, such as BMP9, NaPa, DATS, tetrac, citral, sesamin, and As2S2, among others. The cluster also includes terms related to biological processes and pathways, such as PFKFB4 and P2Y2R, as well as specific techniques and methodologies, such as CT20p and DVDMS. Overall, it seems that this cluster relates to a broad range of topics in the fields of biology, chemistry, and medicine.

      Bio Entities: 'BMP9', 'NaPa', 'DATS', 'tetrac', 'CT20p', 'Rac3', 'MONs', 'citral', 'AITC', 'sesamin', 'Asc', 'DMDD', 'DVDMS', 'MYOF', 'Rapa', 'RL2', 'JMJD3', 'PFKFB4', 'P2Y2R', 'nimbolide', 'GOX', 'PEG5K', 'NAF-1', 'Bi(2)O(3)', 'CTet', 'As2S2', 'BRBP1', 'Shp1', 'SeNPs', 'AuNR', 'α-TOS', 'Citral', 'PolyhHb', 'ILEI', 'furanodiene', 'HMME', 'CMDB7', 'Fe2O3', 'EriB', 'AIF-1', 'rhodium (II) citrate', 'CPG2', 'hUC-MSCs', 'PDLLA', 'MoS(2)', 'ApppI', 'PDGF-D', 'Aplidin', 'ZYTP1', 'LYG-202'

  • Cluster 4    Breast Cancer Diagnostics and Biomarkers

      • This cluster contains terms related to breast cancer and diagnosis, such as different types of breast carcinoma (DCIS, LCIS, ALCL), specific cell types (Toker cells, myofibroblastoma), diagnostic techniques (STIR, rFOV), and treatments (motesanib, dyskerin). Therefore, I would label this cluster as "Breast Cancer Diagnosis and Treatment".

      Bio Entities: 'LCH', 'mammary hamartoma', 'SA DCIS', 'Toker cells', 'mammary myofibroblastoma', 'LGASC', 'HCWs', 'IFLBC', 'ABDE', 'MGACA', 'Ag-NORs', 'MIDC', 'nonpalpable breast carcinoma', 'ICPC', 'AdCCs', 'NPBL', '99mTc phytate', 'NC-LCIS', 'feruglose', 'OMSP', 'STIR', 'STK1', 'P/F LCIS', 'rFOV', 'breast-ALCL', 'microRNA20b', 'SMSGs', 'gadoteric acid', 'IFX', 'gadofosveset', 'dyskerin', 'ECAD', '(89)Sr', 'MnDPDP', 'AP-LCIS', 'DMIST', 'CRMc', 'ALNMs', 'motesanib', 'FBLs', '3CB', 'IMPCa', 'ASLN', 'microRNA320a', 'NMMN', 'Resovist', 'REIS', "anti-CEA Fab'", 'MSGCs', 'c Kit'